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Yuan-Yuan Hu1†, Rong Zheng2†, Chong Guo2 and Yu-Ming Niu1,3*Abstract
Background: Association between Cyclin D1 (CCND1) polymorphism and cervical cancer risk are conflicting with
published articles. We performed a meta-analysis to investigate the association between CCND1 G870A polymorphism
and cervical cancer risk.
Methods: PubMed, Embase and CNKI data were researched to conduct a meta-analysis on the associations between
CCND1 G870A polymorphism and cervical cancer risk. Ten published case–control studies including 2,864 patients with
cervical cancer and 3,898 controls were collected in this meta-analysis. Odds ratio (OR) with 95% confidence interval
(CI) were applied to assess the relationship; meta-regression, sensitivity analysis and cumulative analysis were also
conducted to guarantee the strength of results.
Results: Overall, no significant association between CCND1 G870A polymorphism and cervical cancer risk were found
in allele contrast (A vs. G: OR = 1.02, 95% CI = 0.88-1.19, P = 0.76 I2 = 74.5%), codominant model (GA vs. GG: OR = 0.98,
95% CI = 0.77-1.26, P = 0.90 I2 = 69.1%; AA vs GG: OR = 1.03, 95% CI = 0.75-1.41, P = 0.85 I2 = 75.9%), dominant
model (GA + AA vs. GG: OR = 1.00, 95% CI = 0.78-1.28, P = 0.99 I2 = 72.3%) and recessive model (AA vs GG + GA:
OR = 1.06, 95% CI = 0.85-1.23, P = 0.62, I2 = 70.1%). Similarly, in the stratified analysis by ethnicity, study design and
genotyping type, no significant association detected in all genetic models either.
Conclusions: Our meta-analysis indicated that CCND1 G870A might be not the crucial risk factor for the
development of cervical cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/13000_2014_168
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Cervical cancer is one of the most common malignant
diseases; it is the third most commonly diagnosed cancer
and the fourth leading cause of cancer death in females
with approximately 529,800 new cases and 275,100
deaths among females in 2008 worldwide [1].* Correspondence: n4oneone@126.com
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unless otherwise stated.Cervical cancer is a multifactorial and multistep disease.
Innate immune deficiency, environmental aggravation, and
genetic mutation have been considered as important patho-
poiesis factors. New molecular epidemical studies revealed
that human papillomavirus (HPV), particularly HPV 16
and 18 infections may be the common and important
factor contributing to the development of cervical can-
cer, which is known to cause approximately 70% of cer-
vical cancers [2,3].
Abnormal cell proliferation is an important step in can-
cer development. Cyclins are a family of proteins that con-
trol cell progression through the cell cycle by activatingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.diagnosticpathology.org/content/9/1/168cyclin-dependent kinase (CDK) enzymes [4]. Cyclin D1
(CCND1) is a major regulatory protein that serves a crit-
ical function in the transition from G1 to S phase by bind-
ing to CDK4 and CDK6 to promote cell cycle progression
during cell division [5]. Over-expression of CCND1 will
induce tumor cells to pass the G1/S checkpoint of the cell
cycle. Several studies have found that amplification of
CCND1 and the aberrant expression of protein are associ-
ated with cell proliferation and poor prognosis in some
cancers, such as head and neck cancer [6], lung cancer [7],
and breast cancer [8].
Recently, molecular epidemiologic studies have di-
rected considerable attention toward the association be-
tween genetic mutation and cancer susceptibility. Single-
nucleotide polymorphisms (SNPs) are the most common
type of genetic variation among people. The change in a
nucleotide may alter gene functions and may influence
protein expression, which could inhibit or promote cell
proliferation and increase susceptibility to cancer devel-
opment. In 1995, Betticher et al. [9] reported a syn-
onymous SNP (G870A) in the CCND1 gene. The A
allele has a longer half-life than the G allele and has
been postulated to increase CCND1 level. Such increase
promotes the proliferation of abnormal cells and the es-
cape of these cells from apoptosis.
Catarino et al. published the first research about the
association between CCND1 G870A polymorphism and
cervical cancer risk in 2005 [10]. Since then, a large
number of epidemiological studies have been conducted,
but conclusions were inconsistent. In 2014, a recent
meta-analysis was conducted by Wu et al., which only
demonstrated that no significant association existed be-
tween CCND1 G870A polymorphism and cervical can-
cer risk. More detailed analysis on subgroup of study
design, genotyping type and heterogeneity was not con-
ducted [11]. We therefore performed the comprehensive
meta-analysis to clarify the relationship between the
CCND1 G870A polymorphism and cervical cancer risk
with all published studies.
Methods
Search strategy
Three electronic databases, including Pubmed, Embase,
and China National Knowledge Infrastructure (CNKI),
were searched with the terms “CCND1”, “Cyclin D1”,
“cervical cancer”, and “polymorphism” for studies pub-
lished from 1995 to June 2014. Additional studies were
identified through manual searches of the references of
original studies or review articles on the topic of interest.
Only studies published in English or Chinese were in-
cluded. All studies selected for our meta-analysis met
the following criteria: (a) observational (case–control or
prospective) studies on the association between CCND1
G870A polymorphism and cervical cancer risk, (b)sufficient published data for estimating an odds ratio
(OR) and 95% confidence interval (CI), and (c) the lar-
gest or most recent samples were selected when they
overlapped with other studies.
Data extraction
Data from all included studies were extracted independ-
ently by two investigators (Niu and Zheng). The extracted
data included the name of the first author, publication
date, country of origin, sources of controls, racial descent
of the study population (categorized as Asian, Caucasian,
and Mixed), number of different genotypes, and Hardy-
Weinberg equilibrium (HWE) in controls.
Statistical analysis
The strength of the association between CCND1 G870A
polymorphism and cervical cancer was evaluated by ORs
with 95% CI, comprised with allele contrast (A vs. G),
codominant model (GA vs. GG, AA vs. GG), dominant
model (GA + AA vs. GG), and recessive model (AA vs.
GG + GA). The HWE of the control group was assessed,
and a P value of less than 0.05 was considered significant
disequilibrium. Stratified analyses were used to evaluate
ethnicity, study design, and genotyping type technique.
Heterogeneity was explored with the use of a chi-squared
test, and the quantity of heterogeneity was measured by
the I2 statistic. I2 values of 25%, 50%, and 75% represent
low, moderate, and high heterogeneity, respectively. The
OR of each model was estimated by using the fixed-effects
model (Mantel–Haenszel method) when I2 ≤ 50%; other-
wise, the random-effects model (DerSimonian and Laird
method) was used. Meta-regression analyses were per-
formed to assess potential covariates that can predict inter-
tribal heterogeneity. Publication bias was assessed on the
basis of modified Egger’s bias test and Begg’s funnel plot.
Statistical analysis was performed by using STATA versions
11.0 (Stata Corporation, College Station, TX). Two-sided
P value (P < 0.05) was considered statistically significant.
Results
Study characteristic
A total of 25 possible articles were searched in Pubmed
(n = 12), Embase (n = 9), and CNKI (n = 4) (Figure 1).
Nine duplicates and three irrelevant references were ex-
cluded through abstract screening. Ten published case–
control studies involving 2,864 patients with cervical
cancer and 3,898 controls met our inclusion criteria
[10,12-20]. The data included from each study on differ-
ent populations are presented in Table 1. Only two stud-
ies deviated from HWE in control populations [13,15].
Meta-analysis
Overall, no significant association was found between
CCND1 G870A polymorphism and cervical cancer risk
Figure 1 Flow diagram of the study selection process.
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http://www.diagnosticpathology.org/content/9/1/168in this meta-analysis (Table 2). Values of ORs with 95% CI
were as follows: allele contrast (A vs. G: OR = 1.02, 95%
CI = 0.88-1.19, P = 0.76 I2 = 74.5%); codominant model
(GA vs. GG: OR = 0.98, 95% CI = 0.77-1.26, P = 0.90 I2 =
69.1%; AA vs GG: OR = 1.03, 95% CI = 0.75-1.41, P = 0.85Table 1 Characteristics of case–control studies on CCND1 G87
the meta-analysis





Catarino 2005 Portugal Caucasian Healthy base 143 1
Jeon 2005 Korean Asian Hospital base 222 3
Catarino 2008 Portugal Caucasian Hospital base 226 2
Satinder 2008 India Asian Healthy base 150 1
Thakur 2009 India Asian Hospital base 200 2
Castro 2009 Sweden Caucasian Population base 952 1
Ni 2011 China Asian Hospital base 300 3
Warchoł 2011 Poland Caucasian Healthy base 129 2
Wang 2012 China Asian Population base 327 4
Djansugurova 2013 Kazakhstan Caucasian Healthy base 215 1
aHWE in control.I2 = 75.9%); dominant model (GA + AA vs. GG: OR = 1.00,
95% CI = 0.78-1.28, P = 0.99 I2 = 72.3%, Figure 2); and re-
cessive model (AA vs GG + GA: OR = 1.06, 95% CI = 0.85-
1.23, P = 0.62, I2 = 70.1%). In the succeeding analysis of
HWE studies, similar associations were found. In the strati-
fied analyses of ethnicity, study design, and genotype, no
significant association was found between CCND1 G870A
polymorphism and cervical risk in almost all models. Het-
erogeneity was observed in all five genotype models. Meta-
regression and stratified analyses were conducted, but no
critical factors were found to explain heterogeneity in
the subgroup of ethnicity, design, and genotype either
(e.g., GA + AA vs. GG model: P = 0.321 for ethnicity,
P = 0.819 for design, and P = 0.398 for genotype).
Sensitivity analysis and cumulative analysis
Studies included in the meta-analysis were deleted one by
one to reflect the influence of an individual dataset on the
pooled ORs. The results were consistent (Figure 3 for the
dominant model) for all of the researched genetic models,
indicating that our results were statistically robust. In the
cumulative meta-analysis, the result became negative form
the second study of Jeon et al. [12] (Figure 4).
Publication bias
Funnel plot and Egger’s test were used to estimate pub-
lication bias. The shapes of the funnel plots for all gen-
etic models did not reveal any asymmetrical evidence.
Figure 5 shows the shapes of the funnel plots of the
dominant model used to examine all publications in the
meta-analysis. The result was further supported by the
analysis of the data with Egger’s test. No significant publi-
cation bias was found in this meta-analysis (P = 0.6430A polymorphisms and cervical cancer risk included in




GG GA AA GG GA AA
03 35 64 44 9 55 39 0.091 PCR-RFLP
14 49 112 61 80 160 74 0.730 PCR-RFLP
47 60 103 63 40 138 69 0.037 PCR-RFLP
50 33 64 53 30 65 55 0.184 PCR-RFLP
00 39 94 67 47 119 34 0.006 PCR-RFLP
713 229 463 260 465 837 411 0.367 Multiplex PCR and
hybridization
12 48 160 92 70 137 105 0.051 PCR-RFLP
88 35 65 29 116 123 49 0.100 PCR-RFLP
11 86 180 61 92 203 116 0.859 PCR-RFLP
60 54 103 58 41 78 41 0.752 Direct sequencing
Table 2 Summary ORs and 95% CI of CCND1 G870A polymorphisms and cervical cancer risk
A vs. G GA vs. GG AA vs. GG GA + AA vs. GG AA vs. GG + GA
N* OR 95% CI P I2 (%)a OR 95% CI P I2 (%)a OR 95% CI P I2 (%)a OR 95% CI P I2 (%)a OR 95% CI P I2 (%)a
Total 10 1.02 0.88-1.19 0.76 74.5 0.98 0.77-1.26 0.90 69.1 1.03 0.75-1.41 0.85 75.9 1.00 0.78-1.28 0.99 72.3 1.06 0.85-1.32 0.62 70.1
HWE 8 1.01 0.86-1.18 0.92 71.9 1.08 0.85-1.39 0.52 62.2 1.00 0.72-1.39 0.99 73.1 1.06 0.82-1.36 0.66 68.7 0.97 0.79-1.20 0.79 59.8
Ethnicity
Caucasian 5 0.99 0.79-1.25 0.95 78.1 0.84 0.52-1.35 0.47 82.8 0.92 0.56-1.52 0.75 79.8 0.87 0.54-1.39 0.55 84.5 1.13 0.97-1.30 0.11 1.3
Asian 5 1.05 0.84-1.33 0.65 76.1 1.11 0.88-1.40 0.38 25.6 1.13 0.70-1.83 0.61 77.1 1.10 0.86-1.41 0.44 40.4 1.06 0.68-1.65 0.79 83.9
Design
Healthy base 4 0.98 0.71-1.36 0.91 76.8 0.88 0.47-1.64 0.70 78.1 0.90 0.45-1.78 0.76 77.5 0.89 0.47-1.67 0.71 81.3 1.02 0.79-1.31 0.91 6.7
Hospital base 4 1.11 0.87-1.40 0.40 71.7 0.99 0.60-1.63 0.96 79.4 1.24 0.75-2.07 0.40 74.5 1.06 0.68-1.66 0.80 76.6 1.25 0.82-1.89 0.30 77.1
Population base 2 0.94 0.64-1.39 0.76 91.0 1.08 0.91-1.28 0.38 0.0 0.87 0.39-1.95 0.73 91.2 1.00 0.70-1.44 0.99 72.7 0.85 0.42-1.70 0.64 92.0
Genotyping type
PCR-RFLP 8 1.00 0.82-1.23 0.97 78.3 0.94 0.67-1.33 0.73 75.3 0.98 0.64-1.51 0.93 79.6 0.96 0.68-1.34 0.79 77.3 1.04 0.77-1.40 0.80 74.9
Other 2 1.12 1.01-1.25 0.03 0.0 1.11 0.92-1.33 0.27 0.0 1.25 1.02-1.54 0.03 0.0 1.16 0.97-1.37 0.10 0.0 1.17 0.99-1.39 0.06 0.0
















Figure 2 OR of cervical cancer associated with CCND1 G870A polymorphism for the GA + AA vs. GG model in total.
Hu et al. Diagnostic Pathology 2014, 9:168 Page 5 of 8
http://www.diagnosticpathology.org/content/9/1/168for A vs. G; GA vs. GG: P= 0.427; AA vs. GG: P= 0.558;
(GA + AA) vs. GG: P= 0.423; AA vs. (GG + GA): P= 0.884).
Discussion
Cervical cancer is one of the most dangerous causes of
health deficiency and death worldwide. Epidemiological
studies have revealed that HPV infection is an important
factor contributing to cervical cancer. Furthermore, gene
mutation and abnormal tumor cell proliferation may
serve critical functions in cancer development.Figure 3 Sensitivity analysis through deleting each study to reflect th
AA model.The CCND1 gene is located at chromosome 11q13 and
encodes a key cell cycle regulatory protein with 295 amino
acids. CCND1 is an activator of CDK, which can regulate
cell division by accelerating/decelerating the transition
from G1 to S phase. Over-expression of CCND1 could re-
sult in the aberrant proliferation of DNA damage and the
accumulation of genetic errors. Some SNPs of CCND1
have been reported. The G-to-A mutation is found in a
well-known locus in the boundary of exon 4 and intron 4.
This mutation does not alter any amino acid in the proteine influence of the individual dataset to the pooled ORs in GA +
Figure 4 Cumulative meta-analyses according to publication year in GA + AA vs. GG model.
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http://www.diagnosticpathology.org/content/9/1/168sequence. CCND1 G870A mutation results in an alterna-
tively spliced transcript with a longer half-life than the
CCND1 G allele and thus enables abnormal cells to pass
through the G1-S checkpoint easily. Previous studies have
demonstrated that CCND1 G870A polymorphism is sig-
nificantly associated with the development of various can-
cers, such as breast cancer, prostate cancer, colorectal
cancer, and other cancer types [21-25].
In 2005, Catarino et al. firstly find that CCND1 GG
polymorphism is associated with a 3.45-fold higher risk
for the development of cervical cancer in a Portuguese
population (OR = 3.45, 95% CI: 1.47-7.56) [10]. TheFigure 5 Funnel plot analysis to detect publication bias for GA + AAsame results were reported in a subsequent study in
2008 [13]. Similarly, the report by Wang et al. also dem-
onstrated that the GG/GA genotype increased the cer-
vical cancer risk in a Chinese population (OR = 3.31,
95% CI: 1.28-8.59) [19]. By contrast, Satinder et al. found
that the AA genotype elevated cervical cancer suscep-
tibility in Indians (OR = 3.7, 95% CI: 1.56-8.87) [14].
Thakur et al. also indicated in 2009 that Indian indi-
viduals carrying the AA genotype have a 2.49-fold in-
creased risk of developing cervical cancer (OR = 2.49,
95% CI: 1.51-4.09) [15]. Moreover, other studies by
Castro et al. [16] and Warchol et al. [18] found amodel. Each point represents a separate study.
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http://www.diagnosticpathology.org/content/9/1/168significant association between the A allele and cer-
vical cancer risk. However, some other studies did not
reveal any significant associations between CCND1
G870A polymorphism and cervical cancer.
In 2011, Ni et al. reported the first meta-analysis on
the association between CCND1 G870A polymorphism
and cervical cancer risk [17]. Only five studies were in-
cluded in their review. The small sample size without
stratified and cumulative analysis may have influenced
the strength of their results. Furthermore, in the subse-
quent meta-analysis of Wu et al., the strength of the
conclusion was not enough due to the lack of detailed
analysis [11]. Our updated meta-analysis, which includes
10 case–control studies with 2,864 patients and 3,898
controls, did not reveal any significant associations for
all genetic models even when stratified analysis was con-
ducted according to ethnicity, study design, and geno-
typing type. Moreover, the interaction between G870A
polymorphism, HPV infectious status and cervical can-
cer risk was not conducted due to the deficiency of the
data. Nevertheless, some current studies have shown
that the presence of HPV infection combined with
CCND1 G870A polymorphism might increase the risk
of cervical cancer, which was consistent with the pub-
lished reports with positive expression of HPV infection
in cervical cancer [19,26,27]. Large sample size with
more carefully stratified analyses, more exact statistic
techniques and cumulative analysis and meta-regression
analysis indicated that our results were statistically
robust.
Our analysis has some limitations. First, some hetero-
geneity still exists despite stratified analysis, and the
meta-regression could not be explained successfully.
Second, some environmental factors, such as smoking,
drinking, and HPV infection, were not included in our
meta-analysis because of data deficiency. Third, the sam-
ple size was relatively small, which might have yielded
false results and inaccurate conclusions.Conclusion
In conclusion, this meta-analysis indicated that CCND1
G870A polymorphism may not be a risk factor of cervical
cancer development. Large and well-designed case–con-
trol studies are needed to validate our findings further.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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